UBX - Unity Biotechnology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.16
-0.29 (-2.33%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close12.45
Open12.26
Bid0.00 x 1300
Ask0.00 x 800
Day's Range11.71 - 12.59
52 Week Range10.33 - 24.56
Volume385,656
Avg. Volume260,032
Market Cap514.643M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.59
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Trade prices are not sourced from all markets
  • GlobeNewswire10 hours ago

    UNITY Biotechnology Expands Ongoing UBX0101 Phase 1 Study to Further Evaluate SASP Factors in Osteoarthritis of the Knee

    UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced further expansion of the Phase 1 study of UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee with a cohort of an additional 24 patients at the highest evaluated dose (4mg) (Part B). Part B is intended to supplement the initial Phase 1 trial (Part A) by further evaluating the impact of UBX0101 on specific pro-inflammatory and extracellular matrix modifying factors within the Senescence-Associated Secretory Phenotype (SASP). To measure SASP factors, an adequate volume of synovial fluid is required in the knee joint capsule to collect a sample.

  • PR Newswire15 days ago

    Ascentage Pharma Announces New License with Unity Biotechnology

    ROCKVILLE, Md. and HONG KONG , Jan. 8, 2019 /PRNewswire/ -- Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other ...

  • GlobeNewswire19 days ago

    UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye

    UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging, today announced it has selected UBX1967 as the lead development candidate in the ophthalmology pipeline for advancement into studies to enable an Investigational New Drug (IND) application and executed the compound license agreement for the compound with Ascentage Pharma Group Corp Limited (“Ascentage Pharma”) under a previously agreed compound library agreement. UBX1967 is being evaluated in a range of age-related diseases of the eye, including neovascular age-related macular degeneration, proliferative diabetic retinopathy and diabetic macular edema.

  • This year's Bay Area IPO batch remains up 44% despite market turbulence
    American City Business Journals2 months ago

    This year's Bay Area IPO batch remains up 44% despite market turbulence

    Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.

  • UNITY (UBX) Soars: Stock Adds 5.1% in Session
    Zacks2 months ago

    UNITY (UBX) Soars: Stock Adds 5.1% in Session

    UNITY (UBX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • GlobeNewswire2 months ago

    UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors

    SAN FRANCISCO, Dec. 04, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.

  • Benzinga2 months ago

    The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...

  • GlobeNewswire2 months ago

    UNITY Biotechnology Announces Additional Cohort to Evaluate Higher Dose in Ongoing UBX0101 Phase 1 Study in Osteoarthritis of the Knee

    UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it will include an additional cohort of patients in the Phase 1 single ascending dose clinical study of UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee. UNITY has completed enrollment in Cohorts 1 through 5 (0.1 to 2 mg dose). The amendment follows an interim review of aggregate blinded safety and tolerability, and drug exposure data from these cohorts.

  • GlobeNewswire3 months ago

    UNITY Biotechnology, Inc. to Announce Third Quarter 2018 Financial Results

    SAN FRANCISCO, Oct. 31, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.

  • 24 Bay Area companies have gone public so far this year. Here's how they've done.
    American City Business Journals4 months ago

    24 Bay Area companies have gone public so far this year. Here's how they've done.

    The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.

  • Do You Know Who Else Invests In Unity Biotechnology Inc (NASDAQ:UBX)?
    Simply Wall St.4 months ago

    Do You Know Who Else Invests In Unity Biotechnology Inc (NASDAQ:UBX)?

    If you want to know who really controls Unity Biotechnology Inc (NASDAQ:UBX), then you’ll have to look at the makeup of its share registry. Institutions often own shares in moreRead More...

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Unity Biotechnology and Principia Biopharma

    NEW YORK, NY / ACCESSWIRE / September 17, 2018 / Biotech stocks Unity Biotechnology and Principia Biopharma had exciting trading days on Friday. Shares of Unity saw more gains on Friday after exploding last Thursday when its CEO spoke on CNBC’s “Power Lunch” about the company’s plans. Amazon CEO Jeff Bezos is an investor in the company.

  • Unity (UBX) Catches Eye: Stock Jumps 8.8%
    Zacks4 months ago

    Unity (UBX) Catches Eye: Stock Jumps 8.8%

    Unity (UBX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • Unity Biotech CEO: We can 'absolutely' create drugs that slow, halt or reverse diseases of aging
    CNBC4 months ago

    Unity Biotech CEO: We can 'absolutely' create drugs that slow, halt or reverse diseases of aging

    "The evidence is mounting, both in our company and outside, that you can intervene and you can change the course of these specific diseases," says Unity Biotechnology CEO Keith Leonard.

  • CNBC5 months ago

    Why Jeff Bezos is backing this Silicon Valley scientist who is working on a cure for aging

    Unity Biotechnology is a company designing drugs and treatments that can make a person functional and free of the diseases associated with aging for as long as possible. The company — backed by Jeff Bezos and Peter Thiel —went public in May and is listed on NASDAQ. Of the many people currently involved in searching for ways to slow down or delay the effects of growing older, Nathaniel David might actually have a shot.

  • ACCESSWIRE7 months ago

    Wired News – Alexion Pharma and Complement Pharma Inked Deal to Co-develop Preclinical C6 Complement Inhibitor CP010

    LONDON, UK / ACCESSWIRE / June 13, 2018 / If you want access to our free research report on Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) ("Alexion"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALXN as the Company's latest news hit the wire. On June 11, 2018, the Company announced that it has signed a partnership deal with Complement Pharma to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. Active-Investors.com is currently working on the research report for Unity Biotechnology, Inc. (NASDAQ: UBX), which also belongs to the Healthcare sector as the Company Alexion Pharma.